<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242762</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0504</org_study_id>
    <nct_id>NCT00242762</nct_id>
  </id_info>
  <brief_title>ZD1839 (IRESSA™) in Combination With Docetaxel &amp; Cisplatin in Subjects With Metastatic Head &amp; Neck Cancer</brief_title>
  <official_title>A Phase II Study to Evaluate the Safety and Efficacy of the Combination of ZD1839 (IRESSA™), Docetaxel and Cisplatin in Subjects With Recurrent and/or Metastatic Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the activity of the combination ZD1839,&#xD;
      docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer by&#xD;
      estimating the objective response rate (complete response [CR] and partial response [PR]) at&#xD;
      study closure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumour response (CR and PR) at study closure based on the Response Evaluation Criteria in Solid Tumours (RECIST)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of DLT during the first cycle of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature, incidence and severity of adverse events (AEs) and serious adverse events (SAEs)</measure>
  </secondary_outcome>
  <enrollment>36</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD1839 (IRESSA™)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged 18 and 70 years, inclusive&#xD;
&#xD;
          2. Histologically- or cytologically-confirmed recurrent and/or metastatic SCCHN&#xD;
&#xD;
          3. Primary tumour site of oral cavity, oropharynx, hypopharynx or larynx&#xD;
&#xD;
          4. At least one uni-dimensionally measurable lesion according to the RECIST&#xD;
&#xD;
          5. World Health Organisation (WHO) performance status (PS) of 0 or 1&#xD;
&#xD;
          6. No previous chemotherapy for recurrent or metastatic disease&#xD;
&#xD;
          7. Before subject registration a quality of life questionnaire should be completed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous chemotherapy for recurrent or metastatic disease&#xD;
&#xD;
          2. Less than 6 months since prior induction or adjuvant platinum and/or taxanes&#xD;
             chemotherapy&#xD;
&#xD;
          3. Known severe hypersensitivity to ZD1839 or any of the excipients of this product&#xD;
&#xD;
          4. Known, severe hypersensitivity to docetaxel or cisplatin or any of the excipients of&#xD;
             these products, or to other drugs formulated with polysorbate 80&#xD;
&#xD;
          5. Other co-existing malignancies or malignancies diagnosed within the last 5 years with&#xD;
             the exception of basal cell carcinoma or cervical cancer in situ&#xD;
&#xD;
          6. Any unresolved chronic toxicity greater than common toxicity criteria (CTC) grade 2&#xD;
             from previous anticancer therapy (except alopecia)&#xD;
&#xD;
          7. Absolute neutrophil count (ANC) less than 1.5 x109/litre (L), platelets less than 100&#xD;
             x 109/L or haemoglobin less than 10 g/dl&#xD;
&#xD;
          8. Serum bilirubin greater than the upper limit of the reference range (ULRR)&#xD;
&#xD;
          9. Serum creatinine greater than 1.5 mg/dl despite adequate rehydration&#xD;
&#xD;
         10. Creatinine clearance less than 60 ml/min assessed in over a 24 hour urine collection&#xD;
&#xD;
         11. As judged by the investigator, any evidence of severe or uncontrolled systemic disease&#xD;
             (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)&#xD;
&#xD;
         12. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 1.5&#xD;
             times the ULRR or alkaline phosphatase (ALP) greater than 2.5 times the ULRR&#xD;
&#xD;
         13. Evidence of any other significant clinical disorder or laboratory finding that makes&#xD;
             it undesirable for the subject to participate in the study&#xD;
&#xD;
         14. Pregnancy or breast feeding (women of child-bearing potential)&#xD;
&#xD;
         15. Concomitant use of phenytoin, carbamazepine, rifampicin, or barbiturates, or St John's&#xD;
             Wort&#xD;
&#xD;
         16. Treatment with a non-approved or investigational drug within 30 days before Day 1 of&#xD;
             study treatment&#xD;
&#xD;
         17. Any evidence of clinically active interstitial lung disease (patients with chronic&#xD;
             stable radiographic changes who are asymptomatic need not be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Spain Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>October 20, 2005</study_first_submitted>
  <study_first_submitted_qc>October 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2005</study_first_posted>
  <last_update_submitted>January 25, 2011</last_update_submitted>
  <last_update_submitted_qc>January 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2011</last_update_posted>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Cancer of Head and Neck</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Head Cancer</keyword>
  <keyword>Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

